Synthesis of TPEN variants to improve cancer cells selective killing capacity.


Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
06 2019
Historique:
received: 27 08 2018
revised: 28 01 2019
accepted: 15 03 2019
pubmed: 27 3 2019
medline: 23 9 2020
entrez: 27 3 2019
Statut: ppublish

Résumé

TPEN is an amino chelator of transition metals that is effective at the cellular and whole organism levels. Although TPEN of often used as a selective zinc chelators, it has affinity for copper and iron and has been shown to chelate both biologically. We have previously shown that TPEN selectively kills colon cancer cells based on its ability to chelate copper, which is highly enriched in colon cancer cells. The TPEN-copper complex is redox active thus allowing for increased ROS production in cancer cells and as such cellular toxicity. Here we generate TPEN derivatives with the goal of increasing its selectivity for copper while minimizing zinc chelation to reduce potential side effects. We show that one of these derivatives, TPEEN despite the fact that it exhibits reduced affinity for transition metals, is effective at inducing cell death in breast cancer cells, and exhibits less toxicity to normal breast cells. The toxicity effect of the both chelators coupled to the metal content of the different cell types reveals that they exhibit their toxicity through chelating redox active metals (iron and copper). As such TPEEN is an important novel chelators that can be exploited in anti-cancer therapies.

Identifiants

pubmed: 30913468
pii: S0045-2068(18)30836-8
doi: 10.1016/j.bioorg.2019.03.045
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Ethylenediamines 0
Organometallic Compounds 0
Reactive Oxygen Species 0
Copper 789U1901C5
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine R9PTU1U29I

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

366-372

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Stephanie Schaefer-Ramadan (S)

Department of Physiology and Biophysics, Weill Cornell Medicine - Qatar, Doha, Qatar.

Maciej Barlog (M)

Department of Chemistry, Texas A&M University at Qatar, P.O. Box 23874, Doha, Qatar.

Jim Roach (J)

Pre-Medical Education, Weill Cornell Medicine - Qatar, Doha, Qatar.

Mohammed Al-Hashimi (M)

Department of Chemistry, Texas A&M University at Qatar, P.O. Box 23874, Doha, Qatar.

Hassan S Bazzi (HS)

Department of Chemistry, Texas A&M University at Qatar, P.O. Box 23874, Doha, Qatar.

Khaled Machaca (K)

Department of Physiology and Biophysics, Weill Cornell Medicine - Qatar, Doha, Qatar. Electronic address: khm2002@qatar-med.cornell.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH